Navigation Links
Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
Date:3/12/2008

termittent dosing by both subcutaneous injection and brief (1-2 hour) intravenous (IV) infusion. The maximally tolerable dose (MTD) on a once-per-week for 3 weeks schedule was identified. The follow-on study using the MTD administered on a twice-per- week for 3 weeks schedule has also been completed.

Genta expects to incorporate this new schedule into the ongoing melanoma trial with Abraxane(R) and Temodar(R). These new schedules may ultimately obviate the need for treatment via continuous IV infusion. Abstracts describing results of these studies have been submitted to the 2008 ASCO meeting.

G4544, A New Oral Drug for Skeletal Diseases, Enters Clinical Trials

In late 2007, Genta completed the initial Phase 1 study of G4544, the Company's proprietary small molecule that is intended to treat diseases associated with accelerated bone loss. G4544 contains the active ingredient in Ganite(R), a highly effective drug whose market potential has been constrained by a requirement for continuous IV infusion. No drug-related adverse experience was observed in 30 subjects who received G4544 over a 5- fold dosing range. Further clinical and pharmacokinetic results have been submitted to the 2008 ASCO meeting.

G4544 Development Strategy: The Company has improved the G4544 manufacturing process. Following review and approval of this change, Genta will seek FDA guidance on the 505(b)(2) regulatory pathway, which may shorten development time by allowing use of bioequivalence studies rather than trials to demonstrate efficacy and safety. In this case, Genta owns the NDA for Ganite and has exclusive ownership of important trade secrets, including but not limited to detailed pharmacokinetics and long-term animal toxicology of the active ingredient. The 505(b)(2) approach enables potential approval in the currently approved indication (cancer-related hypercalcemia), in parallel with development in other indications. Low doses of the active ingredient have als
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
2. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
3. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
4. Genta Clinical Programs Featured at American Society of Hematology Meeting
5. Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
6. Genta Incorporated Announces Third Quarter 2007 Financial Results
7. Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
8. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
11. Inclinix Announces New Patent for Expert System Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...The Study Demonstrates microRNAs Extracted From a ...ffective Clinical Biomarkers for a Wide Range of ... Proprietary Technology, Rosetta Genomics is Curre...o Detect Colon Cancer, REHOVOT, Israel and JERSEY...ll/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG), a lea...
(Date:9/4/2008)...nother Roche first in TaqMan(R) real-time PCR test... lab, PLEASANTON, Calif., Sept. 4 /PRNewswir...s approved the Roche COBAS(R) TaqMan(R) HBV Test,... DNA approved in the U.S.,The test uses Roche,s re...epatitis B virus DNA in a patient,s blood. Doctors...
(Date:9/4/2008)...ivotal Study Seeks to Enroll 750 Women at More Tha...4 /- QuatRx Pharmaceuticals, a,privat...lopment and,commercialization of compounds to trea...s, today announced that it has initiated a second,...ablets), the company,s,estrogen-free oral therapy ...
(Date:9/4/2008)... Optimizing Patient Identification for Ta... of Personalized Treatment HUNTINGTON BEACH, Ca...ire/ -- Agendia, a world leader in molecular cance...tPrint(R), a new diagnostic test that,allows physi...ion levels of,the estrogen receptor (ER), progeste...
Breaking Medicine Technology:Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum 2Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum 3Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum 4FDA Approves First Hepatitis B Viral Load Test 2FDA Approves First Hepatitis B Viral Load Test 3QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 2QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 3Agendia Launches TargetPrint(R) for Breast Cancer Patients 2DiObex and Camurus Sign License Agreement for the Development of DIO 901 in FluidCrystal 28R 29 Extended Release Technology 4031 1DiObex and Camurus Sign License Agreement for the Development of DIO 901 in FluidCrystal 28R 29 Extended Release Technology 4031 2Jazz Pharmaceuticals Inc Announces Expansion of Senior Debt 4030 1Jazz Pharmaceuticals Inc Announces Expansion of Senior Debt 4030 2Misys and Allscripts Create a Leader in Healthcare Software 4027 1Reducing HD risk naturally post menopause 14530 1Reducing HD risk naturally post menopause 14530 2
...ter damage caused by,flooding over the weekend, FD...pcoming Antiviral Drugs Advisory Committee,meeting... for,maraviroc 300 milligram tablets. Originally s...aluation and Research Advisory Committee,Conferenc... the,meeting has been relocated to , Crown Plaza H...
...-- Sirion Therapeutics,Inc., an ophthalmic-focuse...it has received orphan drug designation from the F...al therapy,ganciclovir, for the treatment of acut...keted by Laboratoires Thea in Europe under,the bra...o,Virgan(R) for the United States from Laboratoire...
Other Medicine Technology:FDA Announces Change of Location Notice for Upcoming Advisory,Committee Meeting 2Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic,Drug to Treat Viral Eye Infection 2
(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
(Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
(Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
(Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2
Plump Infants Getting Obese Later In Life In More Cases
...t Johns Hopkins University claims that the drug Vi...mance// in men could also reduce the effect of hor...usly thought, drugs like Viagra can in fact alter ...y when the heart is stimulated by hormones,' said ...
...osely watching the ‘Avian Flu’ that is spreading t...rmed a task force to tackle this emergency. The ta...vedi and includes secretaries of health, environme...istries. The inter-ministerial task force is to fo...
...t depression may not be the only factor-probing ad...rs might therefore need to watch out for other men... World Health Organization re-examined the occurre... in 894 cases of completed suicides among young pe...
Other Medicine News:Health News:Viagra Halves Effect Of Hormonal Stress On Heart 2Health News:Multi targeted approach required for suicide prevention in adolescents 2
Features and Benefits: 1-12channel pipette This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-A
...ell plates in mind, Pipetman Ultra Multichannel is...tions: PCR* sequencing, immunology assays, series ...mond Tips from Gilson's patented Rocky Rack system...e productivity.,* PCR process is covered by US pat...
...ion, ergonomics, and value!, Comfortable feel and...andle , Finer control while pipetting with smooth,...ction with long, lever tip ejector , Completely au...ion without the need for recalibration , Easy-to-r...
Finnpipette Focus multichannel pipettes speed up repeat dispensing of reagents into microplates, with super blow-out for 0.1-10 l volumes. The improved ergonomic design of Finnpipette Focus multichan
Medicine Products: